Cancers (Mar 2022)

Value of c-MET and Associated Signaling Elements for Predicting Outcomes and Targeted Therapy in Penile Cancer

  • Anita Thomas,
  • Kimberly Sue Slade,
  • Roman A. Blaheta,
  • Sascha D. Markowitsch,
  • Philipp Stenzel,
  • Katrin E. Tagscherer,
  • Wilfried Roth,
  • Mario Schindeldecker,
  • Martin Michaelis,
  • Florian Rothweiler,
  • Jaroslav Cinatl,
  • Robert Dotzauer,
  • Olesya Vakhrusheva,
  • Maarten Albersen,
  • Axel Haferkamp,
  • Eva Juengel,
  • Jindrich Cinatl,
  • Igor Tsaur

DOI
https://doi.org/10.3390/cancers14071683
Journal volume & issue
Vol. 14, no. 7
p. 1683

Abstract

Read online

Whereas the lack of biomarkers in penile cancer (PeCa) impedes the development of efficacious treatment protocols, preliminary evidence suggests that c-MET and associated signaling elements may be dysregulated in this disorder. In the following study, we investigated whether c-MET and associated key molecular elements may have prognostic and therapeutic utility in PeCa. Formalin-fixed, paraffin-embedded tumor tissue from therapy-naïve patients with invasive PeCa was used for tissue microarray (TMA) analysis. Immunohistochemical staining was performed to determine the expression of the proteins c-MET, PPARg, β-catenin, snail, survivin, and n-MYC. In total, 94 PeCa patients with available tumor tissue were included. The median age was 64.9 years. High-grade tumors were present in 23.4%, and high-risk HPV was detected in 25.5%. The median follow-up was 32.5 months. High expression of snail was associated with HPV-positive tumors. Expression of β-catenin was inversely associated with grading. In both univariate COX regression analysis and the log-rank test, an increased expression of PPARg and c-MET was predictive of inferior disease-specific survival (DSS). Moreover, in multivariate analysis, a higher expression of c-MET was independently associated with worse DSS. Blocking c-MET with cabozantinib and tivantinib induced a significant decrease in viability in the primary PeCa cell line UKF-PeC3 isolated from the tumor tissue as well as in cisplatin- and osimertinib-resistant sublines. Strikingly, a higher sensitivity to tivantinib could be detected in the latter, pointing to the promising option of utilizing this agent in the second-line treatment setting.

Keywords